Ibex Wealth Advisors Acquires New Holdings in Thermo Fisher Scientific Inc. $TMO

Ibex Wealth Advisors bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, HoldingsChannel.com reports. The fund bought 6,687 shares of the medical research company’s stock, valued at approximately $3,875,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. High Note Wealth LLC grew its holdings in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares during the period. Swiss RE Ltd. bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $28,000. Beacon Financial Strategies CORP purchased a new position in Thermo Fisher Scientific in the fourth quarter worth about $29,000. Olistico Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Finally, Core Wealth Advisors LLC bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $30,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $472.73 on Wednesday. The company has a market capitalization of $175.68 billion, a P/E ratio of 25.99, a P/E/G ratio of 2.10 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99. The firm’s 50 day simple moving average is $478.34 and its two-hundred day simple moving average is $525.54. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. During the same period last year, the firm earned $5.15 EPS. The company’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts recently issued reports on TMO shares. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their price objective for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Robert W. Baird decreased their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Finally, Piper Sandler assumed coverage on Thermo Fisher Scientific in a report on Thursday, June 11th. They set a “neutral” rating and a $510.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $608.95.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.